Neila De Pooter

Nice, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Impact of autoimmune diseases or inflammatory manifestations on response and outcome in high-risk myelodysplastic syndromes and chronic myelomonocytic leukemia.

Impact of autoimmune diseases or inflammatory manifestations on response and outcome in high-risk myelodysplastic syndromes and chronic myelomonocytic leukemia.

Journal: Leukemia research

Published: August 18, 2025

International Prognostic Scoring System, Revised International Prognostic Scoring System, and Molecular International Prognostic Scoring System Had No Identical Prognostic Power Depending on Treatment in Myelodysplastic Syndromes.

International Prognostic Scoring System, Revised International Prognostic Scoring System, and Molecular International Prognostic Scoring System Had No Identical Prognostic Power Depending on Treatment in Myelodysplastic Syndromes.

Journal: Acta haematologica

Published: June 30, 2025

Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial.

Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical Trial.

Journal: Acta haematologica

Published: February 25, 2025

F2c.*C20209T mutation in patients with a history of thrombosis: A case report, retrospective 2 site-results and review of the literature.

F2c.*C20209T mutation in patients with a history of thrombosis: A case report, retrospective 2 site-results and review of the literature.

Journal: International journal of laboratory hematology

Published: December 23, 2023

APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation: Response from original authors Toulon et al.

APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation: Response from original authors Toulon et al.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 20, 2021

APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation.

APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation.

Journal: Journal of thrombosis and haemostasis : JTH

Published: November 12, 2020

Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in patients with non-high pre-test probability: Clinical performance and cost-effectiveness analysis.

Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in patients with non-high pre-test probability: Clinical performance and cost-effectiveness analysis.

Journal: Journal of thrombosis and haemostasis : JTH

Published: October 05, 2020

Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents.

Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents.

Journal: Journal of thrombosis and haemostasis : JTH

Published: April 14, 2020

Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges.

Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges.

Journal: Thrombosis and haemostasis

Published: December 16, 2015

Showing 1-9 of 9

Last Updated: 09/26/2026